A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

NCT03783403 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

206

Enrollment

INDUSTRY

Sponsor class

Stopped Business objectives have changed.

Conditions

Neoplasms

Interventions

DRUG: CC-95251
DRUG: Rituximab
DRUG: Cetuximab

Sponsor

Celgene